SCHEMBL1965890

SCHEMBL1965890

CC(C)(C)OC(=O)N(Cc1cccc(Cl)c1)n1cccc1

nearest known ligand 0.47

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
RIPK1 Q13546 1/20 0.47
CTSL P07711 1/20 0.40
TSHR P16473 1/20 0.40
RECQL P46063 1/20 0.40
AOC3 Q16853 1/20 0.39
KMT2A Q03164 1/20 0.38
KDM4E B2RXH2 2/20 0.38
PTPRC P08575 1/20 0.38
PTPRG P23470 1/20 0.38
HTR2C P28335 1/20 0.38
SLC6A4 P31645 1/20 0.38
PKM P14618 1/20 0.37
PYCR1 P32322 1/20 0.37
SMN1; SMN2 Q16637 1/20 0.37
MAOA P21397 2/20 0.37
MAOB P27338 2/20 0.37
ALOX5 P09917 1/20 0.37
L3MBTL1 Q9Y468 1/20 0.36
TAS2R14 Q9NYV8 1/20 0.36
KCNQ2 O43526 1/20 0.36

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL1965400 0.86 GAA (0.40) KMT2AKDM4ESMN1; SMN2
SCHEMBL1965544 0.85 RIPK1 (0.47) RIPK1TSHRKMT2ASMN1; SMN2MAOB
SCHEMBL1964950 0.84 AKT1 (0.46) RIPK1CTSLKMT2AHTR2CSLC6A4
SCHEMBL1966223 0.83 ALDH1A1 (0.42) KMT2AKDM4ESMN1; SMN2MAOBL3MBTL1
SCHEMBL1965084 0.80 CTSB (0.40) KMT2ASLC6A4PYCR1
SCHEMBL21987970 0.79 RIPK1 (0.51) RIPK1CTSLTSHRRECQLAOC3
SCHEMBL1966140 0.78 NPC1 (0.39) TSHRKMT2APYCR1MAOAMAOB
SCHEMBL1966131 0.78 KDM1A (0.42) RIPK1KMT2A
SCHEMBL1965931 0.77 L3MBTL1 (0.43) TSHRKMT2ASMN1; SMN2L3MBTL1TAS2R14
SCHEMBL7705226 0.76 RIPK1 (0.48) RIPK1CTSLTSHRRECQLAOC3

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-2334682-B1 PYRROLO [ 1, 2 -B] PYRIDAZINE DERIVATIVES AND THEIR USE AS HIF MODULATORS FIBROGEN INC (US) 2017-10-04 EP disclosed
US-8217043-B2 Compounds and methods for their use FIBROGEN, INC. (US) 2012-07-10 US disclosed
EP-2334682-A1 PYRROLO [ 1, 2 -B] PYRIDAZINE DERIVATIVES AND THEIR USE AS HIF MODULATORS Fibrogen, Inc. (US) 2011-06-22 EP disclosed
WO-2010022240-A1 PYRROLO [ 1, 2 -B] PYRIDAZINE DERIVATIVES AND THEIR USE AS HIF MODULATORS FIBROGEN, INC. (US) 2010-02-25 WO disclosed
US-20100047367-A1 COMPOUNDS AND METHODS FOR THEIR USE FIBROGEN, INC. 2010-02-25 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20100047367-A1 COMPOUNDS AND METHODS FOR THEIR USE HIF1AN, HIF1A, EGLN3 RIPK1 3787/4885CTSL 1685/4885TSHR 3312/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.